Acasti Pharma Inc. (ACST) |
| 3.37 0.13 (4.01%) 10-25 16:00 |
| Open: | 3.4268 |
| High: | 3.448 |
| Low: | 3.2 |
| Volume: | 27,682 |
| Market Cap: | 34(M) |
| PE Ratio: | -2.36 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 4.97 |
| Resistance 1: | 4.22 |
| Pivot price: | 3.91 |
| Support 1: | 3.01 |
| Support 2: | 2.50 |
| 52w High: | 3.6 |
| 52w Low: | 1.98 |
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.
Financials
| EPS | -1.430 |
| Book Value | 5.860 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -11.6 |
| Return on Equity (ttm) | -18.6 |
Company news
Fri, 25 Oct 2024
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc. - GlobeNewswire
Fri, 07 Jul 2023
Acasti Pharma Announces 1-for-6 Reverse Stock Split - PR Newswire
Tue, 24 Jan 2023
Acasti Pharma to Present at Lytham Partners Investor Select Conference on January 31 - FinancialContent
Mon, 07 Nov 2022
Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022 - FinancialContent
Mon, 14 Feb 2022
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022 - GlobeNewswire
Wed, 12 May 2021
About Us - FinancialContent
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
